Elocon 0.1% w/w Ointment
Authorisation PA23198/010/002 · Organon Pharma (Ireland) Limited
- Licence holder
- Organon Pharma (Ireland) Limited (all products →)
- Active substance
- Mometasone furoate
- Clinical trials
- 8 clinical trials →
- Dosage form
- Ointment
- Route of administration
- Cutaneous use
- ATC codes
- D07AC, D07AC13
- First authorised
- 20/12/1993
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Mometasone furoate: supply and approvals
24 authorised products on the HPRA list contain Mometasone furoate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 32 years (since 20 December 1993). The HPRA list marks it as marketed in Ireland.
Other medicines with Mometasone furoate in Ireland
22 other products on the HPRA list contain Mometasone furoate, from 9 licence holders; 5 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Elocon 0.1% w/w Cream | Organon Pharma (Ireland) Limited | National authorisation (PA) | Marketed |
| Mometasone 50 microgram/dose, Nasal spray, Suspension | Rowex Ltd | National authorisation (PA) | Marketed |
| NASONEX 50 micrograms/actuation Nasal Spray, Suspension | Organon Pharma (Ireland) Limited | National authorisation (PA) | Marketed |
| Rhinex Relief 50 micrograms/actuation Nasal spray, suspension | Rowex Limited, | National authorisation (PA) | Marketed |
| Ryaltris 25 microgram/actuation + 600 microgram/actuation nasal spray, suspension | Glenmark Pharmaceuticals s.r.o. | National authorisation (PA) | Marketed |
| Asmanex Twisthaler 200 micrograms Inhalation Powder | Organon Pharma (Ireland) Limited | National authorisation (PA) | Not marketed |
| Asmanex Twisthaler 400 micrograms Inhalation Powder | Organon Pharma (Ireland) Limited | National authorisation (PA) | Not marketed |
| Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules | Novartis Europharm Limited | Centralised EU authorisation | Not stated |
| Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules | Novartis Europharm Limited | Centralised EU authorisation | Not stated |
| Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules | Novartis Europharm Limited | Centralised EU authorisation | Not stated |
| Bemrist Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules | Novartis Europharm Limited | Centralised EU authorisation | Not stated |
| Bemrist Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules | Novartis Europharm Limited | Centralised EU authorisation | Not stated |
Other substances in ATC group D07AC
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 2 other active substances share the group D07AC with this product:
Betamethasone valerate (3) · Betamethasone (2)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Organon Pharma (Ireland) Limited holds 55 products on the HPRA list, with 22 different active substances; 42 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.